RxDoctor Payments Data

Gohar Ghazarian, MD

Internal Medicine · Willard, OHNPI 1407894090

Payments from drug & device makers

$326in general payments, 2019–2025

Across 33 payments — averaging $9.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$130
  • AbbVie$55
  • Lilly USA, LLC$43
  • AstraZeneca$36
  • GSK$21
  • Dexcom, Inc.$18
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk20$130
AbbVie3$55
Lilly USA, LLC3$43
AstraZeneca3$36
GSK1$21
Dexcom, Inc.1$18
Bayer1$11
Pfizer1$11

How this compares

$326 in reported general payments places this provider in the 60th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$106,896
Medicare patients
252
Services billed
1,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$42,485
OzempicSemaglutide40$39,931
XareltoRivaroxaban44$36,839
TrulicityDulaglutide25$33,924
EliquisApixaban42$25,657
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$16,726
MounjaroTirzepatide15$16,379
Breo ElliptaFluticasone/Vilanterol24$9,820
SymbicortBudesonide/Formoterol Fumarate26$8,641
Albuterol Sulfate HfaAlbuterol Sulfate222$7,422
Spiriva RespimatTiotropium Bromide13$6,489
Advair HfaFluticasone Propion/Salmeterol14$6,003
Gabapentin282$3,065
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,768
Omeprazole225$2,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$43$50,30340 claims
Novo NordiskOzempic$130$39,93140 claims
PfizerEliquis, Premarin$11$27,50753 claims
GSKBreo Ellipta$21$9,82024 claims
AstraZenecaSymbicort$36$8,64126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Willard

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →